LENZ Therapeutics, Inc. short interest in 2024
In 2024, LENZ Therapeutics, Inc.'s disclosed short interest ran from 2.02% of shares outstanding on 12 Jan 2024 to 9.18% on 31 Dec 2024, a change of +7.16 percentage points. The year's high was 9.18% on 31 Dec 2024 and its low 0.82% on 30 Apr 2024, averaging 5.60% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.39 days on 13 Dec 2024. Full history: LENZ Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 2.02% (12 Jan 2024)
- End of year
- 9.18% (31 Dec 2024)
- Change
- +7.16 pp
- High
- 9.18% (31 Dec 2024)
- Low
- 0.82% (30 Apr 2024)
- Average
- 5.60%
- Highest days to cover
- 21.39 (13 Dec 2024)
- SEC filings marked
- 7
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 2.02% | 8.41 | |
| 31 Jan 2024 | 1.38% | 6.01 | |
| 15 Feb 2024 | 1.28% | 8.56 | |
| 29 Feb 2024 | 1.21% | 7.33 | 10-K filed |
| 15 Mar 2024 | 1.51% | 1.04 | |
| 30 Apr 2024 | 0.82% | 3.02 | |
| 15 May 2024 | 4.21% | 6.72 | 10-Q filed, results (8-K) |
| 31 May 2024 | 5.03% | 6.34 | |
| 14 Jun 2024 | 5.88% | 9.39 | |
| 28 Jun 2024 | 7.00% | 4.32 | |
| 15 Jul 2024 | 7.83% | 12.88 | |
| 31 Jul 2024 | 7.57% | 20.59 | |
| 15 Aug 2024 | 7.65% | 17.01 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 7.21% | 20.69 | |
| 13 Sep 2024 | 6.99% | 9.34 | |
| 30 Sep 2024 | 7.08% | 9.76 | |
| 15 Oct 2024 | 7.31% | 14.21 | |
| 31 Oct 2024 | 7.53% | 11.79 | |
| 15 Nov 2024 | 7.94% | 11.79 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 8.24% | 21.00 | |
| 13 Dec 2024 | 8.23% | 21.39 | |
| 31 Dec 2024 | 9.18% | 12.55 |
See also: LENZ Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.